The shares of Edwards Lifesciences Corporation (NYSE:EW) has been pegged with a rating of Neutral by BTIG Research in its latest research note that was published on February 06, 2020. BTIG Research wasn’t the only research firm that published a report of Edwards Lifesciences Corporation, with other equities research analysts also giving their opinion on the stock. Oppenheimer advised investors in its research note published on January 10, 2020, to Outperform the EW stock while also putting a $280 price target. The stock had earned In-line rating from Evercore ISI Markets when it published its report on January 02, 2020. That day the Evercore ISI set price target on the stock to $324. The stock was given Buy rating by Canaccord Genuity in its report released on October 24, 2019, the day when the price target on the stock was placed at 260. Piper Jaffray was of a view that EW is Overweight in its latest report on September 23, 2019. BofA/Merrill thinks that EW is worth Buy rating. This was contained in the firm’s report on July 24, 2019 in which the stock’s price target was also moved to 225.
Amongst the analysts that rated the stock, 1 have recommended investors to sell it, 9 believe it has the potential for further growth, thus rating it as Hold while 12 advised investors to purchase the stock. The consensus currently stands at a Overweight while its average price target is $262.16. The price of the stock the last time has raised by 36.89% from its 52-Week high price while it is -8.41% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 45.19.
The shares of the company dipped by -1.88% during the trading session on Wednesday, reaching a low of $224.67 while ending the day at $226.81. During the trading session, a total of 1.37 million shares were traded which represents a -4.23% decline from the average session volume which is 1.31 million shares. EW had ended its last session trading at $231.15. Edwards Lifesciences Corporation currently has a market cap of $48.17 billion, while its P/E ratio stands at 62.76, while its P/E earnings growth sits at 4.99, with a beta of 0.79. Edwards Lifesciences Corporation debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 2.70 EW 52-week low price stands at $165.69 while its 52-week high price is $247.64.
The company in its last quarterly report recorded $1.46 earnings per share which is below the predicted by most analysts. The Edwards Lifesciences Corporation generated 1.19 billion in revenue during the last quarter. In the second quarter last year, the firm recorded $1.41 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 9.59%. Edwards Lifesciences Corporation has the potential to record 6.26 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Jefferies published a research note on January 07, 2020 where it informed investors and clients that State Street Corporation (NYSE:STT) is now rated as Buy. Their price target on the stock stands at $92. Even though the stock has been trading at $79.78/share, analysts expect it to surge by 0.81% to reach $90.06/share. It started the day trading at $81.82 and traded between $80.30 and $80.43 throughout the trading session.
A look at its technical shows that STT’s 50-day SMA is 79.17 while its 200-day SMA stands at 64.54. The stock has a high of $85.89 for the year while the low is $48.62. The stock, however, witnessed a rise in its short on 01/31/20. Compared to previous close which recorded 4.64 M shorted shares, the short percentage went higher by 3.33%, as 4.79M EW shares were shorted. At the moment, only 1.30% of State Street Corporation shares were sold short. The company’s P/E ratio currently sits at 13.98, while the P/B ratio is 1.37. The company’s average trading volume currently stands at 2.67M shares, which means that the short-interest ratio is just 1.73 days. Over the past seven days, the company moved, with its shift of 0.49%. Looking further, the stock has raised 10.19% over the past 90 days while it gained 56.27% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Massachusetts Financial Services . sold more STT shares, decreasing its portfolio by -2.27% during the last quarter. This move now sees The Massachusetts Financial Services . selling -655,113 shares in the last quarter, thus it now holds 28,263,579 shares of STT, with a total valuation of $2,137,574,480. The Vanguard Group, Inc. meanwhile bought more STT shares in the recently filed quarter, changing its stake to $2,127,608,110 worth of shares.
Similarly, Longview Partners LLP increased its State Street Corporation shares by 0.19% during the recently filed quarter. After buying 20,438,555 shares in the last quarter, the firm now controls 39,600 shares of State Street Corporation which are valued at $1,545,767,915. In the same vein, BlackRock Fund Advisors increased its State Street Corporation shares by during the most recent reported quarter. The firm sold 28,264 shares during the quarter which increased its stakes to 17,932,295 shares and is now valued at $1,356,219,471. Following these latest developments, around 0.40% of State Street Corporation stocks are owned by institutional investors and hedge funds.